Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Daiichi Sankyo
Cipla
Dow
Teva
Chubb
US Army
Federal Trade Commission
Deloitte
US Department of Justice

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,619,001

« Back to Dashboard

Which drugs does patent 7,619,001 protect, and when does it expire?

Patent 7,619,001 protects TECFIDERA and is included in one NDA.

This patent has forty-six patent family members in thirty countries.
Summary for Patent: 7,619,001
Title:Utilization of dialkylfumarates
Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
Inventor(s): Joshi; Rajendra Kumar (Zurich, CH), Strebel; Hans-Peter (Muri, CH)
Assignee: Biogen IDEC International GmbH (Zug, CH)
Application Number:11/765,578
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 7,619,001

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING MULTIPLE SCLEROSIS ➤ Subscribe
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF TREATING MULTIPLE SCLEROSIS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,619,001

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany198 53 487Nov 19, 1998

Non-Orange Book US Patents Family Members for Patent 7,619,001

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,915,310 Utilization of dialkylfumarates ➤ Subscribe
6,509,376 Utilization of dialkyfumarates ➤ Subscribe
7,320,999 Dimethyl fumarate for the treatment of multiple sclerosis ➤ Subscribe
8,524,773 Utilization of dialkylfumarates ➤ Subscribe
7,803,840 Utilization of dialkylfumarates ➤ Subscribe
7,612,110 Utilization of dialkylfumarates ➤ Subscribe
8,759,393 Utilization of dialkylfumarates ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,619,001

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey 200101204 ➤ Subscribe
Slovakia 285601 ➤ Subscribe
Slovakia 5762001 ➤ Subscribe
Slovenia 1131065 ➤ Subscribe
Russian Federation 2215524 ➤ Subscribe
Serbia 49995 ➤ Subscribe
Yugoslavia 29901 ➤ Subscribe
Portugal 1131065 ➤ Subscribe
Poland 226074 ➤ Subscribe
Poland 205948 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Novartis
Mallinckrodt
Julphar
Chinese Patent Office
Boehringer Ingelheim
Colorcon
Chubb
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot